12 results about "Trimethoprim" patented technology

This invention provides an anti-trimethoprim single-chain antibody for detecting trimethoprim-like drug residues, its preparation method, and its application. The amino acid sequences of the single-chain antibody are shown in SEQ ID3, SEQ ID4, and SEQ ID6. Compared with traditional monoclonal antibodies, the single-chain antibody has lower production costs, is simpler to prepare, and is easier to manipulate at the gene level. This invention utilizes trimethoprim-specific monoclonal hybridoma cells and employs phage display technology to screen for high-affinity single-chain antibodies. A single-chain antibody mutant with even higher affinity was successfully obtained through computer simulation combined with site-directed mutagenesis. Based on this mutant, an ic-ELISA was established for the detection of trimethoprim residues in animal-derived foods, meeting the needs of practical applications.

The present application belongs to the technical field of wastewater treatment, and particularly relates to a seawater breeding wastewater antibiotic removal method based on oyster shell composite filler. Fine gravel, oyster shell and functional mineral are compounded in a fixed volume ratio of 2:1:1, and are laid in a structure with a limited particle size range and homogeneity without stratification. A salinity-directed salt-tolerant domestication process and a tidal intermittent operation mode of 48h hydraulic retention + 24h emptying and reoxygenation are matched, and salt-tolerant functional bacterial flora of Proteobacteria, Paracoccus and Shigella are enriched. The present application can adapt to a wide range of salinity conditions of 10‰-30‰, relieve high salt inhibition and ion competition, simultaneously and efficiently remove three typical antibiotics of conventional pollutants, sulfamethoxazole, trimethoprim and enrofloxacin, and reduce resistance genes. The sulfamethoxazole removal rate can reach 93.94% under the condition of 30‰ high salinity, the system runs stably and has strong adaptability, and has certain engineering application value and large-scale popularization potential in the field of seawater breeding wastewater treatment.

The invention discloses an external antibacterial medicine composition as well as a preparation method and application thereof, and belongs to the technical field of antibacterial medicines. The external antibacterial pharmaceutical composition provided by the invention comprises a medicinal active component and a pharmaceutically acceptable carrier, wherein the medicinal active component comprises polymyxin B sulfate, trimethoprim sulfate and lidocaine; every 10 g of the antibacterial pharmaceutical composition for external use is prepared from the following components in parts by weight: 40000 to 60000 U of polymyxin B sulfate, 0.08 to 0.16 g of trimethoprim sulfate and 0.30 to 0.35 g of lidocaine. The pharmaceutical composition disclosed by the invention has broad-spectrum inhibition on multiple drug-resistant bacteria such as common gram-negative drug-resistant bacteria and acinetobacter baumannii on a wound surface, synchronously plays a synergistic role in relieving inflammatory response of the wound surface and relieving local pain, and remarkably improves the medication safety and the comprehensive treatment effect while ensuring excellent antibacterial activity.

This application relates to the field of biotechnology, and particularly to primer pairs, primer-probe compositions, PCR premixes, kits, and methods for detecting multiple respiratory pathogens. Nucleic acid sequences are shown in primer pairs as indicated by SEQ ID NO: 1-2, 4-5, 7-8, 10-11, 13-14, 16-17, 19-20, 22-23, 25-26, 28-29, 31-32, 34-35, 37-38, and 40-41. For target respiratory pathogens, this application designs specific amplification primer pairs, paired with suitable probes, enabling the simultaneous detection of eight targets. Furthermore, the detection process avoids interference from heme, trimethoprim, sulfamethoxazole, amphotericin B, itraconazole, fluconazole, azithromycin, adrenaline, and lidocaine hydrochloride in the test sample. It exhibits good anti-interference properties and shows no cross-reactivity with *Rhodococcus equi*, *Candida tropicalis*, and *Candida krusei*.

The present disclosure provides a system for treating melioidosis, comprising a first antimicrobial agent comprising trimethoprim at a subinhibitory concentration and a second antimicrobial agent comprising a FolE2 enzyme inhibitor selected from dehydrocostus lactone, parthenolide, or β-lapachone, wherein the combination of the first antimicrobial agent and the second antimicrobial agent exhibits chemical synthetic lethality against Burkholderia pseudomallei while having minimal effect on commensal bacteria. The subinhibitory concentration of trimethoprim ranges between 5 μM and 30 μM. The FolE2 enzyme inhibitor acts as a mechanism-based inhibitor that covalently modifies a catalytic cysteine residue (Cys154) of the FolE2 enzyme. The combination exhibits greater than 90% growth suppression against Burkholderia pseudomallei. Methods for treating melioidosis and identifying antimicrobial drug targets using chemical synthetic lethality screening approaches are also provided.

The application discloses a test paper strip and a test method for detecting fluoroquinolones, sulfonamides, tetracyclines and trimethoprim drug residues in aquatic products, and belongs to the technical field of drug detection. A preparation method comprises the following steps: synthesizing a trimethoprim hapten; synthesizing quinolone, sulfonamide and tetracycline haptens; preparing an immunogen and a coating agent; preparing a monoclonal antibody; preparing a gold-labeled antibody; and pretreating and assembling. The application can simultaneously complete the detection of fluoroquinolones, sulfonamides, tetracyclines and trimethoprim residues in aquatic products by constructing a four-class drug integrated detection scheme, and does not need to use different detection tools or batch detection for a single drug. In the actual detection scene of aquatic products, the repeated steps of sample processing and detection operation can be greatly reduced, the waste of aquatic product samples caused by multiple sampling can be avoided, the overall detection period can be shortened, and the rapid quality control demand of aquatic products from fishing / cultivation to circulation can be met.

The present invention provides a novel pharmaceutical composition of polymyxin B / trimethoprim and rifampicin, as well as a preparation method and topical ocular application thereof (e.g., treatment of ocular infections).

This application provides a *Staphylococcus pseudoci* AT8 strain for degrading antibiotics and its application. The *Staphylococcus pseudoci* is a species of Staphylococcus (…). Staphylococcus The *Staphylococcus pseudocarpa* species, having a 16S rDNA sequence as shown in SEQ ID NO:1, is named... Staphylococcus pseudoxylosus AT8, deposited on November 20, 2025 at the Guangdong Provincial Center for Microbial Culture Collection, accession number: GDMCC No: 67323. This application pertains to *Staphylococcus pseudocarpa*. Staphylococcus pseudoxylosus AT8 can achieve a degradation rate of over 90% for trimethoprim and tilmicosin, and over 78% for enrofloxacin. Furthermore, this application enriches the antibiotic-degrading bacterial strain library, promotes the control of new antibiotic pollutants in livestock and poultry manure and farmland soil, and facilitates the resource-based treatment and safe utilization of solid waste, demonstrating broad application prospects.

The invention relates to a method for synthesizing a diaveridine intermediate, which comprises the following steps: (a) adding dimethyl sulfoxide, potassium hydroxide and 3-dimethylaminopropionitrile into a reaction container, and heating to 65-75 DEG C; then adding veratraldehyde, and stirring to react for 2-3 hours to obtain a first reaction solution; and (b) adding ethanol and aniline into the first reaction solution, then dropwise adding an acid-containing solution, carrying out heat preservation reaction at 75-85 DEG C for 2-3 hours, cooling, crystallizing, and drying to obtain the diaveridine intermediate. Therefore, the side reaction for synthesizing the diaveridine intermediate can be inhibited, so that the reaction conditions are simplified, and the yield of the product is improved.

The invention provides a method for preparing a trimethoprim key intermediate, which comprises the following steps: (a) adding an aprotic solvent, methoxypropionitrile and an alkali-alcohol mixed solution into a reaction container, then adding 3, 4, 5-trimethoxybenzaldehyde, heating and stirring for reaction; (b) adding aniline into a product obtained in the step (a), dropwise adding an acid solution to adjust the pH value to 2-3, and continuously heating to react until the TLC detection reaction is finished; (c) cooling and crystallizing the product in the step (b), filtering to obtain a filter cake, and drying to obtain a trimethoprim key intermediate; the chemical structural formula of the trimethoprim key intermediate is shown in the specification. The key intermediate which can be directly used for the next step can be obtained by a one-step method without treatment and at a high conversion rate.

The invention relates to the technical field of biology, in particular to a primer pair, a primer probe composition, a PCR premix, a kit and a method for detecting multiple respiratory pathogens. The invention discloses a primer pair with nucleic acid sequences as shown in SEQ ID NO: 1-2, 4-5, 7-8, 10-11, 13-14, 16-17, 19-20, 22-23, 25-26, 28-29, 31-32, 34-35, 37-38 and 40-41. Aiming at a target respiratory pathogen, a specific amplification primer pair is designed and is matched with a proper probe, so that eight-target joint detection can be realized, and the influence of heme, trimethoprim, sulfamethoxazole, amphotericin B, itraconazole, fluconazole, azithromycin, epinephrine and lidocaine hydrochloride in a detection sample can be avoided in the detection process; the anti-interference performance is good, and cross reaction with rhodococcus equi, candida tropicalis and candida krusei does not exist.

The application discloses a method for rapid proliferation and genetic transformation regeneration of Radix Morindae Officinalis embryogenic callus and belongs to the technical field of plant tissue culture. The method comprises the following steps: firstly, inoculating Radix Morindae Officinalis embryogenic callus into a liquid culture medium to carry out suspension culture to obtain Radix Morindae Officinalis embryogenic callus cell groups; then adding the callus cell groups into a bacterial infection liquid to carry out infection; and then transferring the callus cell groups to a differentiation culture medium to carry out culture to obtain Radix Morindae Officinalis transgenic regenerated plants. The suspension culture medium provided by the application can realize large-scale and rapid proliferation of Radix Morindae Officinalis embryogenic callus, and the embryogenic callus cell groups obtained by the proliferation have a good growth state. In the process of establishing the genetic transformation system of Radix Morindae Officinalis, the method of directly carrying out differentiation culture after co-culture is adopted, the differentiation culture medium does not add resistance screening, and an antibacterial agent, i.e., trimethoprim, is added, so that the transgenic plants are regenerated with high efficiency.